Login to Your Account

Mixed bag for biopharma as Q1 earnings pour in

By Marie Powers
News Editor

Thursday, April 28, 2016

Celgene Corp. coasted through currency exchange headwinds. Vertex Pharmaceuticals Inc. focused on its emerging pipeline after soft Orkambi sales. And Gilead Sciences Inc. fell shy of analyst expectations. Amgen Inc. saved the day with higher-than-expected profits and raised guidance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription